FDA approves Adbry for atopic dermatitis.
Adbry can be used with or without topical corticosteroids.
The approval of Adbry is based on safety and efficacy results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase III trials, which included nearly 2,000 adult patients with moderate-to-severe atopic dermatitis. Safety data was evaluated from a pool of five randomized, double-blind, placebo-controlled trials, including ECZTRA and ECZTRA 3, a dose-finding trial, and a vaccine response trial. Adbry will be available in a 150 mg/mL prefilled syringe for subcutaneous injection with an initial dose of 600 mg followed by 300 mg every other week.
Related news and insights
Incyte and Maruho Co., Ltd. announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte's selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan.
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving RG 3637 (lebrikizumab) combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75) in the phase III ADhere trial, Eli Lilly has announced at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference.
More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company announced at the American Academy of Dermatology (AAD) Annual Meeting.